NASHVILLE, Tenn. – March 24, 2009– Praxis, a company specializing in centralized patient recruitment for clinical research studies has released new information on the recently launched 2.0 version of its online study management technology PraxisDirect. The enhanced features not only offer sponsors and site staff added benefits but provide Praxis the capability to predict study outcomes with even greater accuracy. PraxisDirect, comprised of 7 years of study metrics, allows Praxis to use relational modeling to predict the enrollment of upcoming study projects and to develop recruitment strategies to further expedite that enrollment. “During our protocol feasibility analysis we utilize PraxisDirect’s wealth of data and analytical ability to assist us in predicting enrollment outcomes and in optimizing the appropriate recruitment strategy” states Donna Beasley, VP of Operations with Praxis, “Our sponsor are benefiting from the results.”
In a recent succession study within a Phase II program, PraxisDirect’s predictive modeling assisted in developing a recruitment program that led to increased site staff motivation that resulted in a 22% increase in sites’ patient screening rate over the prior similar study. This study also finished enrollment 10 months early. The sponsor in this study noted, “One of their (Praxis) many useful tools is their website system, PraxisDirect. PraxisDirect has been such a fantastic tool in providing us accurate and real time recruitment results. The website is very user friendly and is a resource we refer to on a daily basis to review number of patient inquiries, enrollment, upcoming screening projections, site performance, etc.”
PraxisDirect 2.0 is a study management technology that collects Praxis pre-qualified candidate data through the centralized recruitment center, as well as integrates data from sponsors’ IVRS/CTMS systems. Multilingual pre-screening with detailed analysis allows sponsors conducting global trials increased flexibility and ease as well. Sponsors can view how each site is performing and assess their efficiency with the new PraxisDirect 2.0 site rankings. PraxisDirect 2.0 also features customized homepage dashboard views – for site staff and for sponsors. The dashboard at-a-glance charts, graphs and analyses provide the user with the key results that are most important to them. The enrollment projection indicator tells sponsors continually by how far their studies are on track to exceed enrollment goals. Sponsors see the immediate results of their recruitment investments. Site performance analyses tell Sponsors which sites are taking their pre-qualified referrals and converting them to screened and randomized patients most effectively. All of which allows Praxis the ability to invest recruitment support in the site areas where the sponsor gets the best results. The business intelligence that results and the relational modeling capabilities using the comprehensive store of information make PraxisDirect 2.0 a unique tool in Praxis collective of resources in developing targeted effective recruitment programs.
Praxis Communications, Inc., headquartered in Brentwood, Tenn., provides the pharmaceutical and biotech industries with a wide range of global services for patient recruitment and retention for clinical trials including patient profiling, recruitment planning, centralized fulfillment, media relations, advertising and program management. For more information, call Praxis at (615)312-8207 or visit www.GoPraxis.com.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Ethical, Biosafety, and Scientific Review Considerations in Hematology and Oncology Clinical Trials
September 10th 2024The current oncology and hematology drug development pipeline features a wide array of large molecule therapeutics. As a result, clinical trial protocols have grown more complex, requiring sponsors, CROs, and research sites to tackle a variety of challenges that were less common with older, more traditional therapies.